 Eli Lilly Wins FDA Approval for Alimta as First-Line Lung Cancer TreatmentEli Lilly and Co announced it has won the Food and Drug Administration approval for its drug Alimta as a first-line treatment for patients with advanced non-small cell lung cancer.
09-29-2008 |
12:59 hs.
Author: Cate Kirby
|
Indianapolis-based Eli Lilly said the U.S. health regulator agency has approved their drug Alimta - in combination with cisplatin - for patients with locally advanced and metastatic non-small cell lung cancer. In the U.S. alone, there are 180,000 new cases of this condition annually. Alimta was approved in 2004 as a treatment for patients with malignant pleural mesothelioma, and then as a single agent for the second-line treatment of patients with lung cancer after prior chemotherapy treatment. This third approved use of Alimta was based on a trial including 1,725 patients, in which the median survival rate was increased to 10.3 months. Alimta generated $ 522 million dollars in the first half of 2008.  Publish comment:
|
Estimated reading time: 0:33
Word count: 741
|
